BPMC Logo

Blueprint Medicines Corporation (BPMC) 

NASDAQ
Market Cap
$5.73B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
577 of 960
Rank in Industry
313 of 550

Largest Insider Buys in Sector

BPMC Stock Price History Chart

BPMC Stock Performance

About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing …

Insider Activity of Blueprint Medicines Corporation

Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $40.58M worth of Blueprint Medicines Corporation stock.

On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $349,105 and sold $21.08M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.

List of Insider Buy and Sell Transactions, Blueprint Medicines Corporation

2024-12-19Saledirector
15,000
0.0237%
$89.77$1.35M+0.55%
2024-12-18SaleCHIEF OPERATING OFFICER
2,274
0.0037%
$95.91$218,098-5.89%
2024-12-12SalePRINCIPAL ACCOUNTING OFFICER
1,819
0.0029%
$93.26$169,636+1.85%
2024-11-29SaleCHIEF EXECUTIVE OFFICER
2,353
0.0037%
$96.60$227,304-1.03%
2024-11-27SaleCHIEF OPERATING OFFICER
2,274
0.0036%
$95.10$216,257+0.30%
2024-11-21Saledirector
9,824
0.0151%
$94.87$932,003-1.58%
2024-11-20Saledirector
10,000
0.0157%
$93.77$937,655+0.31%
2024-11-07Saledirector
5,000
0.0079%
$102.00$510,000-5.92%
2024-10-03SalePRESIDENT, R & D
3,633
0.0058%
$89.32$324,500+6.74%
2024-09-09Saledirector
19,702
0.0308%
$85.57$1.69M+5.50%
2024-08-15SaleCHIEF FINANCIAL OFFICER
4,409
0.0071%
$95.23$419,8690.00%
2024-08-05SaleCHIEF COMMERCIAL OFFICER
41,913
0.0663%
$93.19$3.91M-0.44%
2024-07-05SaleCHIEF PEOPLE OFFICER
3,850
0.0066%
$111.20$428,1200.00%
2024-07-03SaleCHIEF PEOPLE OFFICER
8,817
0.0151%
$111.29$981,2440.00%
2024-06-28SaleCHIEF PEOPLE OFFICER
333
0.0006%
$111.15$37,0130.00%
2024-06-21SaleCHIEF PEOPLE OFFICER
74,034
0.1169%
$104.19$7.71M-10.59%
2024-06-05SaleCHIEF SCIENTIFIC OFFICER
4,000
0.0063%
$105.13$420,520-11.25%
2024-06-04SaleCHIEF MEDICAL OFFICER
2,424
0.004%
$104.91$254,302-7.72%
2024-06-03SaleCHIEF SCIENTIFIC OFFICER
2,436
0.0039%
$106.43$259,263-10.28%
2024-06-03SaleCHIEF MEDICAL OFFICER
4,922
0.008%
$106.43$523,848-10.28%

Insider Historical Profitability

2.65%
Haviland KateCHIEF EXECUTIVE OFFICER
150824
0.2374%
$90.15127+10.84%
FMR LLC
264898
0.417%
$90.1519+9.46%
Goldberg Mark Alan
10812
0.017%
$90.1516<0.0001%
Demetri George
5822
0.0092%
$90.1519<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$611.61M10.36.45M-2.08%-$12.97M0.01
The Vanguard Group$598.56M10.086.31M+3.19%+$18.5M0.01
T. Rowe Price$592.95M9.986.25M+15.14%+$77.96M0.07
Fidelity Investments$490.38M8.265.17M+18.89%+$77.9M0.03
Wellington Management Company$396.05M6.674.18M-2.37%-$9.6M0.07
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.